Poltreg S.A. (PTG.WA)
PLN 36.0
(4.35%)
PLN 36.0
(4.35%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 7.8 Million PLN | -0.79% |
| 2022 | 7.86 Million PLN | 21741.67% |
| 2021 | 36 Thousand PLN | -90.6% |
| 2020 | 383 Thousand PLN | -38.03% |
| 2019 | 618 Thousand PLN | -80.65% |
| 2018 | 3.19 Million PLN | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 7.55 Million PLN | 0.0% |
| 2024 Q1 | 7.6 Million PLN | 0.0% |
| 2023 Q1 | 8.04 Million PLN | 2.34% |
| 2023 FY | 7.8 Million PLN | -0.79% |
| 2023 Q2 | 7.69 Million PLN | -4.35% |
| 2023 Q4 | 7.8 Million PLN | -7.38% |
| 2023 Q3 | 8.42 Million PLN | 9.43% |
| 2022 Q2 | 27 Thousand PLN | -15.63% |
| 2022 Q1 | 32 Thousand PLN | -11.11% |
| 2022 Q3 | 7.95 Million PLN | 29348.15% |
| 2022 FY | 7.86 Million PLN | 21741.67% |
| 2022 Q4 | 7.86 Million PLN | -1.11% |
| 2021 Q1 | 297 Thousand PLN | -22.45% |
| 2021 Q4 | 36 Thousand PLN | 157.14% |
| 2021 Q3 | 14 Thousand PLN | -86.54% |
| 2021 FY | 36 Thousand PLN | -90.6% |
| 2021 Q2 | 104 Thousand PLN | -64.98% |
| 2020 Q4 | 383 Thousand PLN | 0.0% |
| 2020 FY | 383 Thousand PLN | -38.03% |
| 2020 Q1 | - PLN | 0.0% |
| 2019 FY | 618 Thousand PLN | -80.65% |
| 2018 FY | 3.19 Million PLN | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bioceltix S.A. | 76.33 Thousand PLN | -10119.695% |
| BIOTON S.A. | 12.67 Million PLN | 38.463% |
| Captor Therapeutics Spolka Akcyjna | 1.24 Million PLN | -525.581% |
| Mabion S.A. | 2.94 Million PLN | -164.62% |
| Molecure S.A. | 4.97 Million PLN | -56.778% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Pharmena S.A. | 114 Thousand PLN | -6742.982% |
| Pure Biologics Spólka Akcyjna | 12.85 Million PLN | 39.301% |
| Ryvu Therapeutics S.A. | 365 Thousand PLN | -2037.26% |
| Synthaverse S.A. | 61.2 Million PLN | 87.254% |
| Urteste S.A. | 312 Thousand PLN | -2400.321% |